Haemonetics (HAE)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-23

$118.51+2.02%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Haemonetics’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.7%

+10% or more+5%0%−5%−10% or less

5.78 → 5.82 EPS · FY ending Mar 28, 2028 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q3
Revenue	—	357.78M
EPS	—	1.359
FY 2027 · Annual
Revenue	—	1.42B
EPS	—	5.313
Organic revenue growth	4%–7%	—
FY 2028 · Annual
Revenue	—	1.5B
EPS	—	5.818

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain free cash flow conversion near 80%	Free cash flow remains strong near $210 million annually.	Intact	Free cash flow conversion falls significantly below 80% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Management targets free cash flow conversion near 80% for fiscal 2027. Free cash flow increased to $39.1 million in 2026-Q2 from a much lower level in 2025-Q2, showing progress toward sustaining strong cash flow conversion. Delivery assessment Oct 24, 2026
Operating margin expansion of 50-100 basis points YoY	Profit margins aim to expand 50-100 basis points.	Intact	Operating margin declines or fails to expand by at least 50 bps in FY27	Operating margin: 16.93% FY2027-Q1; GAAP. Published target: >=50 bps YoY expansion. Target percentage unit is not explicit. Source published Aug 6, 202616.930285 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 60919a49-3fb6-4d9a-8658-84ddefbe6b44. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Management targets 50-100 basis points adjusted operating margin expansion for fiscal 2027. Operating margin was 16.9% in 2026-Q2, slightly up from 16.8% in 2025-Q2, indicating limited progress toward margin expansion so far. Delivery assessment Oct 24, 2026
Organic revenue growth of 3-6% for fiscal 2027	A primary condition in Haemonetics's published investment case. The stated target is 3-6% YoY.	Intact	Organic revenue growth falls below 3% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Management raised fiscal 2027 organic revenue growth guidance from 3-6% to 4-7% in 2026-Q2, with first quarter fiscal 2027 organic revenue growth at 5.9%. The trajectory is delivering consistent growth aligned with guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-28 · fmp

FY2028 EPS$5.82

$5.72 → $5.82 · observed estimates

FY2028 revenue$1.50B

$1.47B → $1.50B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$5.72	$1,474,245,146	7 / 9
2026-07-25	$5.72	$1,474,245,146	7 / 9
2026-07-26	$5.72	$1,474,245,146	7 / 9
2026-07-27	$5.72	$1,474,245,146	7 / 9
2026-07-28	$5.72	$1,474,245,146	7 / 9
2026-07-29	$5.72	$1,474,245,146	7 / 9
2026-07-30	$5.72	$1,474,245,146	7 / 9
2026-07-31	$5.72	$1,474,245,146	7 / 9
2026-08-01	$5.72	$1,474,245,146	7 / 9
2026-08-02	$5.72	$1,474,245,146	7 / 9
2026-08-03	$5.72	$1,474,245,146	7 / 9
2026-08-04	$5.72	$1,474,245,146	7 / 9
2026-08-05	$5.72	$1,474,245,146	7 / 9
2026-08-06	$5.72	$1,474,245,146	7 / 9
2026-08-07	$5.72	$1,474,254,237	7 / 9
2026-08-08	$5.72	$1,474,254,237	7 / 9
2026-08-09	$5.72	$1,474,254,237	7 / 9
2026-08-10	$5.72	$1,474,254,237	7 / 9
2026-08-12	$5.72	$1,474,254,237	7 / 9
2026-08-13	$5.72	$1,474,254,237	7 / 9
2026-08-14	$5.72	$1,474,254,237	7 / 9
2026-08-15	$5.72	$1,474,254,237	7 / 9
2026-08-16	$5.72	$1,474,254,237	7 / 9
2026-08-17	$5.72	$1,474,254,237	7 / 9
2026-08-18	$5.72	$1,474,254,237	7 / 9
2026-08-19	$5.72	$1,474,254,237	7 / 9
2026-08-20	$5.74	$1,486,349,042	7 / 9
2026-08-21	$5.74	$1,486,349,042	7 / 9
2026-08-22	$5.74	$1,486,349,042	7 / 9
2026-08-23	$5.74	$1,486,349,042	7 / 9
2026-08-24	$5.74	$1,486,349,042	7 / 9
2026-08-25	$5.74	$1,486,349,042	7 / 9
2026-08-26	$5.74	$1,486,349,042	7 / 9
2026-08-27	$5.74	$1,486,349,042	7 / 9
2026-08-28	$5.74	$1,486,349,042	7 / 9
2026-08-29	$5.74	$1,486,349,042	7 / 9
2026-08-30	$5.74	$1,486,349,042	7 / 9
2026-08-31	$5.74	$1,486,349,042	7 / 9
2026-09-01	$5.74	$1,486,349,042	7 / 9
2026-09-02	$5.74	$1,486,349,042	7 / 9
2026-09-03	$5.74	$1,486,349,042	7 / 9
2026-09-04	$5.74	$1,486,349,042	7 / 9
2026-09-05	$5.74	$1,486,349,042	7 / 9
2026-09-06	$5.74	$1,486,349,042	7 / 9
2026-09-07	$5.74	$1,486,349,042	7 / 9
2026-09-08	$5.74	$1,486,349,042	7 / 9
2026-09-09	$5.74	$1,486,349,042	7 / 9
2026-09-10	$5.74	$1,486,349,042	7 / 9
2026-09-11	$5.74	$1,486,349,042	7 / 9
2026-09-12	$5.74	$1,486,349,042	7 / 9
2026-09-13	$5.74	$1,486,349,042	7 / 9
2026-09-14	$5.74	$1,486,349,042	7 / 9
2026-09-15	$5.74	$1,486,349,042	7 / 9
2026-09-16	$5.74	$1,486,349,042	7 / 9
2026-09-17	$5.74	$1,486,349,042	7 / 9
2026-09-18	$5.74	$1,486,349,042	7 / 9
2026-09-19	$5.74	$1,486,349,042	7 / 9
2026-09-20	$5.78	$1,492,618,933	7 / 9
2026-09-21	$5.78	$1,492,618,933	7 / 9
2026-09-22	$5.78	$1,492,618,933	7 / 9
2026-09-23	$5.78	$1,492,618,933	7 / 9
2026-09-24	$5.78	$1,492,618,933	7 / 9
2026-09-25	$5.78	$1,492,618,933	7 / 9
2026-09-26	$5.78	$1,492,618,933	7 / 9
2026-09-27	$5.78	$1,492,618,933	7 / 9
2026-09-28	$5.78	$1,492,618,933	7 / 9
2026-09-29	$5.78	$1,492,618,933	7 / 9
2026-09-30	$5.78	$1,492,618,933	7 / 9
2026-10-01	$5.78	$1,492,618,933	7 / 9
2026-10-02	$5.78	$1,492,618,933	7 / 9
2026-10-03	$5.78	$1,492,618,933	7 / 9
2026-10-04	$5.78	$1,492,618,933	7 / 9
2026-10-05	$5.78	$1,492,618,933	7 / 9
2026-10-06	$5.78	$1,492,618,933	7 / 9
2026-10-07	$5.78	$1,492,618,933	7 / 9
2026-10-08	$5.78	$1,492,618,933	7 / 9
2026-10-09	$5.78	$1,492,618,624	7 / 9
2026-10-10	$5.78	$1,492,618,624	7 / 9
2026-10-11	$5.82	$1,500,832,396	7 / 9
2026-10-12	$5.82	$1,500,832,396	7 / 9
2026-10-13	$5.82	$1,500,832,396	7 / 9
2026-10-14	$5.82	$1,500,803,151	7 / 9
2026-10-15	$5.82	$1,495,344,524	7 / 9
2026-10-16	$5.82	$1,495,344,524	7 / 9
2026-10-17	$5.82	$1,495,344,524	7 / 9
2026-10-18	$5.82	$1,495,344,524	7 / 9
2026-10-19	$5.82	$1,495,344,524	7 / 9
2026-10-20	$5.82	$1,495,344,524	7 / 9
2026-10-21	$5.82	$1,495,341,796	7 / 9
2026-10-22	$5.82	$1,495,341,796	7 / 9
2026-10-23	$5.82	$1,495,346,205	7 / 9
2026-10-24	$5.82	$1,495,346,205	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	4
2026-06-01	8	3
2026-07-01	8	3
2026-08-01	8	3
2026-09-01	9	3
2026-10-01	9	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Mizuho SecuritiesOct 9 · prior Jun 15

$85.00 → $140.00+64.7%

BarringtonOct 9 · prior Aug 19

$118.00 → $140.00+18.6%

BTIGOct 8 · prior Aug 6

$96.00 → $130.00+35.4%

$0$77.00$154.00

3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain free cash flow conversion near 80%Direct metric needs a verified mapping
Operating margin expansion of 50-100 basis points YoYOperating margin: 16.93%
Organic revenue growth of 3-6% for fiscal 2027Direct metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.8%Typical daily move · historical

Downside history

-40.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Haemonetics outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

HAE is a growth-oriented healthcare business with a sector tailwind, rather than a turnaround story. The long-term thesis is intact, but earnings quality is fragile and overall risk is elevated.

What's priced into Haemonetics

Valuation is neutral versus peers, and the evidence describes expectations as broadly aligned with the business setup. Recent valuation has eased, while the current signal is mildly favorable rather than fully favorable.

What the fundamentals likely do

Near-term, revenue growth and cash generation are progressing: first-quarter fiscal 2027 organic revenue growth was 5.9%, and free cash flow increased from a much lower level a year earlier. Margin expansion is less established, with operating margin only slightly higher year over year in the second quarter, and a guidance reversal would raise credibility concerns.

What Haemonetics hinges on

Over the next one to three years, the thesis hinges on sustaining the raised fiscal 2027 revenue-growth guidance while delivering the targeted margin expansion and cash-flow conversion. Weaker employment data could add pressure to cyclical healthcare names, while continued strong results and guidance from healthcare peers would support the sector backdrop.